APA (7th ed.) Citation

Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., . . . Chen, R. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of clinical oncology, 30(18), 2183. https://doi.org/10.1200/JCO.2011.38.0410

Chicago Style (17th ed.) Citation

Younes, Anas, et al. "Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin's Lymphoma." Journal of Clinical Oncology 30, no. 18 (2012): 2183. https://doi.org/10.1200/JCO.2011.38.0410.

MLA (9th ed.) Citation

Younes, Anas, et al. "Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin's Lymphoma." Journal of Clinical Oncology, vol. 30, no. 18, 2012, p. 2183, https://doi.org/10.1200/JCO.2011.38.0410.